Johnson Adiv A, Andrews-Pfannkoch Cynthia, Nelson Timothy J, Pulido Jose S, Marmorstein Alan D
Department of Ophthalmology, Mayo Clinic, Rochester, MN 55905, USA.
Departments of Cardiovascular Diseases, Molecular Pharmacology & Experimental Therapeutics, Division of General Internal Medicine, Division of Pediatric Cardiology, & Transplant Center, & Center for Regenerative Medicine, Rochester, MN 55905, USA.
Regen Med. 2017 Dec 15. doi: 10.2217/rme-2017-0101.
The comparison of differentiated induced pluripotent stem cells (iPSCs) derived from patients with disease to differentiated iPSCs derived from healthy patients enables powerful disease modeling. By performing an informal retrospective survey of disease modeling studies published in high impact journals, we found that the median and average number of controls used in these studies were 1 and 1.6, respectively. The bulk of these studies did not control for age, gender and ethnicity. Since a large proportion of phenotypic differences observed between iPSC lines are due to genetic variation or variation between lines, this is an insufficient number of controls to confidently rule out standard variation. Future studies need to include more controls and ensure that these controls are appropriately matched for gender, age and ethnicity.
将患有疾病的患者来源的诱导多能干细胞(iPSC)与健康患者来源的分化iPSC进行比较,能够实现强大的疾病建模。通过对发表在高影响力期刊上的疾病建模研究进行非正式的回顾性调查,我们发现这些研究中使用的对照的中位数和平均数分别为1和1.6。这些研究大多未对年龄、性别和种族进行控制。由于在iPSC系之间观察到的大部分表型差异是由于基因变异或系间变异,因此这一对照数量不足以可靠地排除标准变异。未来的研究需要纳入更多对照,并确保这些对照在性别、年龄和种族方面进行适当匹配。